What’s A Fair Price For A Biosimilar In Europe?
Executive Summary
The views of biosimilar manufacturers and payers in Europe still vary widely as to what a “fair price” for a biosimilar should be, what discounts should be offered and when, and how to determine what is an appropriate return on investment, says a new report from Simon Kucher & Partners.